Global Microbial API Market, By Host (Mammalian, Bacterial, Fungal), By Type (Antibody, Peptide, Protein, Small Molecule, Vaccine), By Site (In-house and Outsourced), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 61.21 Bn in 2023 and is expected to exhibit a CAGR of 6.7% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing inorganic growth strategies, such as collaboration between key market players so as to develop API, are expected to drive market growth over the forecast period. For instance, on October 3, 2023, Willow Biosciences Inc., a synthetic biology company, and SUANFARMA, a company specializing in the development, production, and commercialization of active pharmaceutical ingredients (API), jointly announced a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume of anti-infective active pharmaceutical ingredient (API) through precision fermentation. Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process.
Global Microbial API Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.
The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors that has been majorly impacted by the COVID-19 pandemic. It has also affected the growth of the pharmaceutical businesses of various companies globally due to lockdowns implemented by the governments of several countries. The nationwide lockdowns have led to the closure of industrial establishments, except for the manufacturing of essential commodities, and disruptions in the supply chain of pharmaceuticals, APIs, and kits for diagnostic and therapeutic use. For instance, during the COVID-19 pandemic, there was a reduction in non-emergency surgical procedures, which impacted the growth of the market. According to an article published by journal of JAMA Network Open, an open access journal, in December 2021, titled 'Trends in U.S. Surgical Procedures and Health Care System Response to Policies Curtailing Elective Surgical Operations During the COVID-19 Pandemic', the pandemic had affected every aspect of medical care, including the surgical treatments. The article analyzed the surgical data in the U.S. from November 2020 through July 2021 and indicated that the initial shutdown period in March 2020 through April 2020 was associated with a decrease in surgical procedure volumes. After the restrictions were lifted, the rate of surgical procedures rebounded to 2019 levels. This had a negative impact on microbial API market.
Global Microbial API Market: Key Developments
In June 2023, Olon S.p.A., a global company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), announced that it had increased their microbial API manufacturing capacity by 20% at their manufacturing site in Italy.
Browse 44 Market Data Tables and 37 Figures spread through 165 Pages and in-depth TOC on “Global Microbial API market, By Host (Mammalian, Bacterial, Fungal), By Type (Antibody, Peptide, Protein, Small Molecule, Vaccine), By Site (In-house and Outsourced), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/industry-reports/global-microbial-api-market
Key Takeaways of the Global Microbial API Market:
- The global microbial API market is expected to exhibit a CAGR 6.7% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global microbial API market. Moreover, an increasing partnership between key market players in API manufacturing is also expected to drive market growth. For instance, in August 2020, Lonza, a multinational manufacturing company for the pharmaceutical, biotechnology, and nutrition sectors, announced that it had partnered with Servier Laboratories, an international pharmaceutical company, for the manufacturing and supply of L-asparaginase.
- Among regions, North America is expected to be dominant in the global microbial API market, owing to the presence of major players such as Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Lonza, AbbVie Inc., and other key market players contributing to growth in this region.
- Major players operating in the global microbial API market include Merck & Co., Inc., Topfond Pharmaceutical Co., Ltd., DSM, CSPC Pharmaceutical Group Limited., KOLON LIFE SCIENCE, Teva Pharmaceutical Industries Ltd., Lonza, Akums Lifesciences Ltd., AbbVie Inc., Xellia Pharmaceuticals, BASF, Dr. Reddy's Laboratories and Lupin
